Modeling glioblastoma complexity with organoids for personalized treatments

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

6 Scopus Citations
View graph of relations

Author(s)

Related Research Unit(s)

Detail(s)

Original languageEnglish
Pages (from-to)282-296
Journal / PublicationTrends in Molecular Medicine
Volume29
Issue number4
Online published15 Feb 2023
Publication statusPublished - Apr 2023

Abstract

Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM. © 2023 Elsevier Ltd

Research Area(s)

  • brain organoids, drug screening, glioblastoma, tumor microenvironment

Citation Format(s)

Modeling glioblastoma complexity with organoids for personalized treatments. / Raue, Kristen D.; Duffy, Joseph T.; Babak, Maria V. et al.
In: Trends in Molecular Medicine, Vol. 29, No. 4, 04.2023, p. 282-296.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review